Sun Yat-sen Memorial Hospital
中山大学孙逸仙纪念医院
Listed for 22 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
Official links opened and checked on 2026-11-08.
Research at Sun Yat-sen Memorial Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌25 papers led5 open trials led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌10 papers led2 open trials led
- Hepatocellular carcinoma肝细胞癌66 papers led10 open trials led
- Stomach cancer胃癌11 papers led5 open trials led
- Hepatoblastoma肝母细胞瘤2 papers led
- Osteosarcoma骨肉瘤6 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
- Neuroblastoma神经母细胞瘤10 papers led1 open trial led
- Ewing sarcoma尤文肉瘤2 papers led
- Multiple myeloma多发性骨髓瘤1 paper led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病4 papers led
- Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症4 papers led
- Beta thalassaemiaβ 地中海贫血6 papers led
- Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病0 papers led1 open trial led
- IgG4-related diseaseIgG4相关性疾病4 papers led
- Hepatic echinococcosis肝包虫病1 paper led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症3 papers led
- Behçet disease白塞病1 paper led
- IgA nephropathyIgA 肾病7 papers led
- Osteogenesis imperfecta成骨不全症0 papers led
- Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
- Primary sclerosing cholangitis原发性硬化性胆管炎0 papers led
Not listed for: Retinoblastoma, Chordoma, Aplastic anaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 25 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 1.1%.
24 hospitals in Guangzhou for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma
Open trials with this hospital 8
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingEfficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2026-07
- Registry
- NCT07705243
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingEfficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2026-07
- Registry
- NCT07706985
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingEfficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial
- Phase
- Phase 3
- Started
- 2024-05
- Registry
- NCT06438627
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingGP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06455410
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen Memorial Hospital; 7 listed hospitals as study sitesFoshan, Guangzhou, Liuzhou, Nanning, Shantou, Shenzhen
- RecruitingDeep Learning-based sbORN Diagnostic Model
- Phase
- Not given
- Started
- 2024-07
- Registry
- NCT06463392
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingA Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
- Phase
- Phase 2
- Started
- 2024-01
- Registry
- NCT05956587
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChongqing, Fuzhou, Guangzhou, Hangzhou, Linyi, Liuzhou, Nanchang, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingTPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06301165
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesDongguan, Foshan, Guangzhou, Shenzhen, Wuhan
- RecruitingA Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
- Phase
- Not given
- Started
- 2024-04
- Registry
- NCT06308328
Age 18 years to Not stated (registered criteria)
Led by Nanfang Hospital; 9 listed hospitals as study sitesChengdu, Guangzhou, Shanghai, Shaoguan, Shenzhen, Zhuhai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led25
- The role of the CTBP2 mediated glycolytic pathway in nasopharyngeal carcinoma metastasis.
- Capecitabine combined with immunotherapy as maintenance therapy improves survival in recurrent/metastatic nasopharyngeal carcinoma: a retrospective cohort study.
- Efficacy and safety of low-dose vs medium-dose bevacizumab for radiation-induced brain necrosis in nasopharyngeal carcinoma survivors.
- Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial.
- Development and Validation of a Nomogram Model for Predicting Non-keratinizing Nasopharyngeal Carcinoma by Combining Sex and Three EB Virus Antibodies.
- Longitudinal observation of radiation-induced cognitive impairment and emotional dysfunction: Based on animal model and clinical cohort.
- The m6A reader YTHDF1 facilitates nasopharyngeal carcinoma proliferation and migration via c-MYC.
- Single-cell transcriptome analysis reveals evolving tumour microenvironment induced by immunochemotherapy in nasopharyngeal carcinoma.
- IgG4-related disease with nasopharyngeal malignancy-like manifestations.
- Targeting Cancer Mitochondria by Inducing an Abnormal Mitochondrial Unfolded Protein Response Leads to Tumor Suppression.
- Age-specific characteristics of head and neck second primary malignancies in patients treated for nasopharyngeal carcinoma: a retrospective study.
- EBV abortive lytic cycle promotes nasopharyngeal carcinoma progression through recruiting monocytes and regulating their directed differentiation.
- Progression of cognitive dysfunction in NPC survivors with radiation-induced brain necrosis: A prospective cohort.
- A collision tumor of nasopharyngeal carcinoma and primary mantle cell lymphoma in the nasopharynx: a case report and review of the literature.
- Development of a prognostic model to identify the metastatic nasopharyngeal carcinoma patients who may benefit from chemotherapy combination PD-1 inhibitor.
- Effective of metastasis-directed therapy for de novo metastatic nasopharyngeal carcinoma: A propensity score matched analysis.
- C2orf48 promotes the progression of nasopharyngeal carcinoma by regulating high mobility group AT-hook 2.
- A radiomics model for predicting the response to methylprednisolone in brain necrosis after radiotherapy for nasopharyngeal carcinoma.
- Progression and postoperative complications of osteoradionecrosis of the jaw: a 20-year retrospective study of 124 non-nasopharyngeal cancer cases and meta-analysis.
- Establishment and Validation of a Predictive Model for Radiation-Associated Aspiration Pneumonia in Patients with Radiation-Induced Dysphagia after Nasopharyngeal Carcinoma.
- Radiotherapy-Related Neurologic Complications in Patients with Nasopharyngeal Carcinoma: A Multicenter Epidemiologic Study in Southern China.
- Nogo-B promotes invasion and metastasis of nasopharyngeal carcinoma via RhoA-SRF-MRTFA pathway.
- Radiation optic neuropathy diagnosis in nasopharyngeal carcinoma patients with radiation encephalopathy.
- STRESS granule-associated RNA-binding protein CAPRIN1 drives cancer progression and regulates treatment response in nasopharyngeal carcinoma.
- En bloc resection and reconstruction in patients with advanced recurrent nasopharyngeal carcinoma and radiation-induced sarcoma of the head and neck.
Chinese-language papers (not in the count)2
All its trials on ClinicalTrials.gov, any status20
- Deep Learning-based sbORN Diagnostic Model
- Distribution of Bacteria in OME After Radiotherapy For NPC.
- A Retrospective Study Reveals the Relationship Between gp42-IgG Epitopes and EBV-associated NPC
- A Prospective, Randomized, Controlled Clinical Study of BET Combined With Tympanostomy Tube Insertion in the Treatment of Intractable OME After Radiotherapy for NPC
- Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis
- Treatment of Bevacizumab Followed by Steroid in RN
- Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma
- Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis
- Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma
- Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma
- GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
- Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial
- Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy
- Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
- A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
- A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
- TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
- A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
- Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)
- A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens
More papers found outside PubMed (not counted)38
- 1370P Long-term outcomes of paclitaxel, cisplatin, and capecitabine vs. cisplatin and fluorouracil as induction chemotherapy in nasopharyngeal carcinoma: A multicenter randomized clinical trial
- 434 Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study
- 710P Mapping the disparity of nasopharyngeal carcinoma burden across 34 provinces in China, 1990-2040, forecasts with scenarios simulation using deep-learning algorithm
- A Deep-Learning Model Integrating Multi-Modality Data for Predicting the Recurrence of Nasopharyngeal Carcinoma
- A randomized, open-label, multicenter, blank-controlled, phase IV clinical trial of Biyan Qingdu Granula in attenuating acute nose and oral damage in patients undergoing radiotherapy for nasopharyngeal carcinoma.
- AI-Enhanced Automated Planning System for Online Adaptive Radiotherapy in Nasopharyngeal Carcinoma: Development and Prospective Clinical Validation
- Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)
- Development and Performance Evaluation of an LLM-Based Automated Recommendation System for Radiotherapy Treatment Planning
- Effect of induction chemo-immunotherapy on the chance for re-irradiation in high-risk recurrent nasopharyngeal carcinoma: A prospective, single-arm, phase II trial.
- Novel genetic algorithm‐based individual treatment effect scoring model for optimizing decision‐making: Induction chemotherapy in nasopharyngeal carcinoma
- Prior Knowledge-Guided Deep Learning Segmentation Algorithm for Online Adaptive Radiotherapy in Nasopharyngeal Carcinoma
- Updated efficacy, safety and biomarker analysis of a phase 2 study of LBL-007 (alcestobart, an anti-LAG-3 mAb) combined with tislelizumab (an anti–PD-1 mAb) and chemotherapy in previously untreated recurrent or metastatic nasopharyngeal car
- WITHDRAWN: 1386P A deep learning-based time-habitat longitudinal MRI radiomics model for predicting short-term treatment outcomes in locally advanced nasopharyngeal carcinoma: A multi-center study
- 893P Combination of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: An open-label, single-arm, phase II clinical trial
- Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.
- Combination of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) with chemotherapy in anti-PD-1 resistant recurrent or metastatic nasopharyngeal carcinoma: an open-label, single-arm, phase II clinical trial
- SPP1+ tumor-associated macrophages induce radioresistance of nasopharyngeal carcinoma through crosstalk with the tumor microenvironment
- Additional file 3 of FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway
- Data from A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer
- Data from A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer
- Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: An open-label phase II study.
- Enhanced radiosensitivity and chemoradiation efficacy in nasopharyngeal carcinoma via a dual-targeted SPION@polymer hybrid nanosensitizer
- Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial.
- Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 2 of Long noncoding RNA LINC00930 promotes PFKFB3-mediated tumor glycolysis and cell proliferation in nasopharyngeal carcinoma
- Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Efficacy and safety of camrelizumab and apatinib combined with induction chemotherapy and concurrent chemoradiotherapy for stage T any N3M0 nasopharyngeal carcinoma: A phase II QUINTUPLED trial.
- Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: A single-arm phase II study.
- Voxel-based radiomics outlines spatial heterogeneity of cerebral radiation necrosis (RN) associated with bevacizumab (Bev) response in head and neck radiotherapy (RT) patients.
- Capecitabine maintenance therapy after induction chemotherapy in newly diagnosed metastatic nasopharyngeal carcinoma: An open-label, randomized, controlled, phase trial.
- Contouring Methods and Atlas of Organs at Risk
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 10 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.
- Open trials as a site
- 0
- led by another institution
11 hospitals in Guangzhou for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingAdebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07595770
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingCombination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-03
- Registry
- NCT06339619
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led10
- Right versus left thoracic approach esophagectomy for patients with neoadjuvant immunochemotherapy.
- Single-Cell RNA-Seq Reveals the Effect of Commensal Bacteria on the Multistep Development of Esophageal Cancer.
- Nomograms for predicting the prognosis in multiple primary esophageal squamous cell carcinoma.
- Single-cell RNA sequencing reveals the MIF-ACKR3 receptor-ligand interaction between iCAFs and tumor cells in esophageal squamous cell carcinoma.
- CircPDE5A-encoded novel regulator of the PI3K/AKT pathway inhibits esophageal squamous cell carcinoma progression by promoting USP14-mediated de-ubiquitination of PIK3IP1.
- A novel protein encoded by circUBE4B promotes progression of esophageal squamous cell carcinoma by augmenting MAPK/ERK signaling.
- Intratumoral microbiome impacts immune infiltrates in tumor microenvironment and predicts prognosis in esophageal squamous cell carcinoma patients.
- A propensity score-matched analysis of neoadjuvant chemoimmunotherapy versus surgery alone for locally advanced esophageal squamous cell carcinoma.
- HN1L/AP-2γ/PLK1 signaling drives tumor progression and chemotherapy resistance in esophageal squamous cell carcinoma.
- Organoid models combined with genome engineering and epigenome studies to define SOX2 function evolution in esophageal squamous cell carcinoma.
All its trials on ClinicalTrials.gov, any status2
More papers found outside PubMed (not counted)8
- Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway
- Artificial intelligence model for predicting the efficacy of sintilimab plus chemotherapy in treating patients with esophageal squamous cell carcinoma.
- Identification lymph node metastasis in esophageal squamous cell carcinoma using whole slide images and a hybrid network of multiple instance and transfer learning
- 359. INTRATUMORAL MICROBIOME IMPACTS IMMUNE INFILTRATES IN TUMOR MICROENVIRONMENT AND PREDICTS PROGNOSIS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS
- Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma
- MiR-4739 inhibits the malignant behavior of esophageal squamous cell carcinoma cells via the homeobox C10/vascular endothelial growth factor A/phosphatidylinositol 3-kinase/AKT pathway
- Genomic profiling of Chinese esophageal squamous cell carcinoma patients and difference of genomic mutation between Chinese and American cohorts.
- MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel
Cancer
Hepatocellular carcinoma
肝细胞癌Led 66 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.
15 hospitals in Guangzhou for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 13
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingTACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC
- Phase
- Not given
- Started
- 2026-07
- Registry
- NCT07658833
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingCamrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
- Phase
- Phase 3
- Started
- 2025-10
- Registry
- NCT07267806
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingAnlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT07806292
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingPostoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2024-08
- Registry
- NCT06581315
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingmFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria
- Phase
- Phase 2
- Started
- 2024-02
- Registry
- NCT06607107
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingDownstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation
- Phase
- Phase 2
- Started
- 2023-06
- Registry
- NCT05475613
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingInfusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
- Phase
- Phase 3
- Started
- 2023-07
- Registry
- NCT06172205
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingMultimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
- Phase
- Not given
- Started
- 2026-10
- Registry
- NCT07880106
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingFOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation
- Phase
- Phase 1/Phase 2
- Started
- 2025-01
- Registry
- NCT06409637
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingEffect of Prehabilitation During the Conversion Therapy on Postoperative Outcomes in Unresectable Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2025-01
- Registry
- NCT06749678
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07327034
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou
- Not yet recruitingThe Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
- Phase
- Not given
- Started
- 2026-07
- Registry
- NCT07724951
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan University; 6 listed hospitals as study sitesGuangzhou, Harbin, Nanning, Qingdao, Shanghai
- Not yet recruitingSurgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2026-12
- Registry
- NCT07866612
Age 18 years to 80 years (registered criteria)
Led by West China Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led66
- Targeting the Notch1-YY1-ICAM1 Signaling Axis Enhances the Efficacy of Immunotherapy in HCC by Activating CD8+ T-Cell-Driven Cancer Cell Pyroptosis.
- m6A-Modified circRAPGEF1 Interaction with IGF2BP3 Promotes Hepatocellular Carcinoma Progression via Reprogramming Aspartate Metabolism.
- TMEM88 modulates the proliferation and metastasis of HCC via the GSK-3β/β-catenin pathway.
- Multiparametric dual-energy computed tomography radiomics for predicting microvascular invasion in hepatocellular carcinoma.
- circCCNY enhances lenvatinib sensitivity and suppresses immune evasion in hepatocellular carcinoma by serving as a scaffold for SMURF1 mediated HSP60 degradation.
- RPL35A Downregulation Suppresses Hepatocellular Carcinoma Cell Proliferation via NCAPG2 Inactivation.
- LncRNA AFAP1-AS1 promoting residual tumor progression after insufficient radiofrequency ablation by up-regulating macropinocytosis in hepatocellular carcinoma.
- Post-transarterial chemoembolization hypoxia-induced HIF-1α/WNT/β-catenin signaling promotes hepatocellular carcinoma progression via programed death ligand 1 upregulation.
- Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma.
- G6PC1 expression as a prognostic biomarker associated with metabolic reprogramming and tumor microenvironment in hepatocellular carcinoma.
- Unveiling B7/CD28 family proteins in hepatocellular carcinoma: insights into communication and prognostic significance.
- Ribonuclease P/MRP subunit RPP40 coordinates the transcription of pre-rRNA and ribosomal protein genes to promote Hepatocellular carcinoma malignancy.
- Co-Delivery of Chemotherapy and Anti-Angiogenic Lipid via DPPA-LNPs Potentiates Anti-PD-1 Immunotherapy.
- A deep learning-based clinical-radiomics model predicting the treatment response of immune checkpoint inhibitors (ICIs)-based conversion therapy in potentially convertible hepatocelluar carcinoma patients: a tumor marker prognostic study.
- Modulating lipid metabolism by nanoparticles (NPs)-mediated ACSL3 silencing to inhibit hepatocellular carcinoma growth and metastasis.
- Advances in Tumor Microenvironment and Immunotherapeutic Strategies for Hepatocellular Carcinoma.
- Analysis of the optimal patterns of serum alpha fetoprotein (AFP), AFP-L3% and protein induced by vitamin K absence or antagonist-II (PIVKA-II) detection in the diagnosis of liver cancers.
- Safety and efficacy of laparoscopic portal territory fluorescence navigation-guided anatomical liver resection in hepatocellular carcinoma patients.
- MAD2L1 supports MYC-driven liver carcinogenesis in mice and predicts poor prognosis in human hepatocarcinoma.
- A Multifunctional Nanodrug Increases the Therapeutic Sensitivity of Lenvatinib to Hepatocellular Carcinoma by Inhibiting the Stemness of Hepatic Cancer Stem Cells.
- The Taping Game for the Complex G8 Glissonean Approach Is the Most Effective Technique for Laparoscopic Anatomic S8 Resection of Dandelion-Patterned Hepatic Pedicles.
- FAT10 induces immune suppression by upregulating PD-L1 expression in hepatocellular carcinoma.
- Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor for treating unresectable hepatocellular carcinoma.
- Pretransplant immunotherapy increases acute rejection yet improves survival outcome of HCC patients with MVI post-liver transplantation.
- SMYD4 monomethylates PRMT5 and forms a positive feedback loop to promote hepatocellular carcinoma progression.
- CircNUP54 promotes hepatocellular carcinoma progression via facilitating HuR cytoplasmic export and stabilizing BIRC3 mRNA.
- A novel risk score system based on immune subtypes for identifying optimal mRNA vaccination population in hepatocellular carcinoma.
- Integrated analysis reveals an aspartate metabolism-related gene signature for predicting the overall survival in patients with hepatocellular carcinoma.
- Thermal ablation versus liver resection for hepatocellular carcinoma in patients with cirrhosis: a systematic review and meta-analysis of propensity-score matched studies.
- Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial.
- Identification of immunosenescence of unconventional T cells in hepatocellular carcinoma.
- Applying image features of proximal paracancerous tissues in predicting prognosis of patients with hepatocellular carcinoma.
- Design, Synthesis and Evaluation of a Novel Teoptinib Derivative as an Effective Anti-hepatocellular Carcinoma Agent.
- Causal Effect of Immunocytes, Plasma Metabolites, and Hepatocellular Carcinoma: A Bidirectional Two-Sample Mendelian Randomization Study and Mediation Analysis in East Asian Populations.
- Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy.
- Hepatitis B Virus X Protein Represses Expression of Tumor Suppressor PTPN18 in Hepatocellular Carcinoma.
- Atractylenolide II regulates the proliferation, ferroptosis, and immune escape of hepatocellular carcinoma cells by inactivating the TRAF6/NF-κB pathway.
- Downstaging of Hepatocellular Carcinoma Before Liver Transplantation: Current Advances in Selection Criteria and Therapeutic Options.
- Exploring the efficacy of 18F-FDG PET/CT in hepatocellular carcinoma diagnosis: role of Ki-67 index and tumor differentiation.
- Repolarization of macrophages to improve sorafenib sensitivity for combination cancer therapy.
- Remodeling Serine Synthesis and Metabolism via Nanoparticles (NPs)-Mediated CFL1 Silencing to Enhance the Sensitivity of Hepatocellular Carcinoma to Sorafenib.
- Development and validation of web-based prognostic nomograms for massive hepatocellular carcinoma (≥10 cm): A retrospective study based on the SEER database.
- Preoperative prediction of macrotrabecular-massive hepatocellular carcinoma based on B-Mode US and CEUS.
- HMGB1 released from dead tumor cells after insufficient radiofrequency ablation promotes progression of HCC residual tumor via ERK1/2 pathway.
- GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma.
- Integrative analysis of lactylation-related genes and establishment of a novel prognostic signature for hepatocellular carcinoma.
- Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
- Anchoring super-enhancer-driven oncogenic lncRNAs for anti-tumor therapy in hepatocellular carcinoma.
- Cathepsin-facilitated invasion of BMI1-high hepatocellular carcinoma cells drives bile duct tumor thrombi formation.
- Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models.
- Targeting PI3Kγ/AKT Pathway Remodels LC3-Associated Phagocytosis Induced Immunosuppression After Radiofrequency Ablation.
- CircLIFR suppresses hepatocellular carcinoma progression by sponging miR-624-5p and inactivating the GSK-3β/β-catenin signaling pathway.
- Hypoxic Hepatocellular Carcinoma Cells Acquire Arsenic Trioxide Resistance by Upregulating HIF-1α Expression.
- p62 Promotes Malignancy of Hepatocellular Carcinoma by Regulating the Secretion of Exosomes and the Localization of β-Catenin.
- A functional loop between YTH domain family protein YTHDF3 mediated m6A modification and phosphofructokinase PFKL in glycolysis of hepatocellular carcinoma.
- INPP5F translocates into cytoplasm and interacts with ASPH to promote tumor growth in hepatocellular carcinoma.
- Activation of the Notch1-c-myc-VCAM1 signalling axis initiates liver progenitor cell-driven hepatocarcinogenesis and pulmonary metastasis.
- Utility of Sonazoid-Enhanced Ultrasound for the Macroscopic Classification of Hepatocellular Carcinoma: A Meta-analysis.
- Genome-wide identification of microRNA targets reveals positive regulation of the Hippo pathway by miR-122 during liver development.
- SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters.
- Survival analysis between laparoscopic and open hepatectomy for hepatocellular carcinoma: a meta-analysis based on reconstructed time-to-event data.
- Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression.
- miR-4454 Promotes Hepatic Carcinoma Progression by Targeting Vps4A and Rab27A.
- Human umbilical cord mesenchymal stem cells-derived exosomal microRNA-451a represses epithelial-mesenchymal transition of hepatocellular carcinoma cells by inhibiting ADAM10.
- Global analysis of gene expression signature and diagnostic/prognostic biomarker identification of hepatocellular carcinoma.
- Totally laparoscopic anatomic S7 segmentectomy using in situ split along the right intersectoral and intersegmental planes.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status30
- Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
- TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC
- Effect of Prehabilitation During the Conversion Therapy on Postoperative Outcomes in Unresectable Hepatocellular Carcinoma
- Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
- FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation
- Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
- mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria
- Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
- Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation
- Evaluation of the Safety and Effectiveness of Pringle Method Combined With IVC Flow Limiting and Blocking Method in Laparoscopic Hepatectomy Based on Non-restrictive Fluid Therapy Strategy
- Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection
- Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma
- mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC
- Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC
- Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
- TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer
- Surgical Specification and Efficacy Evaluation of Total Laparoscopic Left Liver Resection
- Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
- Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
- The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
- ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification
- A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
- Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
- A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
- A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
- Study of BGB-A317 in Participants With Previously Treated Unresectable HCC
- A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
- Hepatic Resection Versus TACE+RFA for BCLC Stage B Hepatocellular Carcinoma
Cancer
Stomach cancer
胃癌Led 11 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.1%.
15 hospitals in Guangzhou for stomach cancer211 hospitals in China for stomach cancer
Open trials with this hospital 6
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingLarge Language Models Assist in Tumor MDT
- Phase
- N/A
- Started
- 2026-01
- Registry
- NCT07504367
Age 25 years to 33 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingFeasibility and Safety of Robotic Assisted Proximal Gastrectomy With Double-flap Technique for Proximal Early Gastric Cancer
- Phase
- N/A
- Started
- 2024-06
- Registry
- NCT05892289
Age 20 years to 80 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingSintilimab Plus FOLFIRI as Second-line Therapy for Patients With HER2-negative Advanced Gastric Cancer
- Phase
- Phase 2
- Started
- 2026-06
- Registry
- NCT06365008
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingMultimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
- Phase
- Not given
- Started
- 2026-10
- Registry
- NCT07880106
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingLaparoscopic Proximal Gastrectomy With Double-flap Technique Versus Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction for Proximal Early Gastric Cancer
- Phase
- N/A
- Started
- 2023-06
- Registry
- NCT05890339
Age 20 years to 80 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingA Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2022-01
- Registry
- NCT05150691
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led11
- Clinicopathological characterization of gastric amphicrine carcinoma: A case series.
- Discovery of highly potent marine-derived compound Penicolinate H reveals SREBP-1 mediated lipogenesis as a druggable vulnerability in gastric cancer.
- Unraveling the unfolded protein response signature: implications for tumor immune microenvironment heterogeneity and clinical prognosis in stomach cancer.
- A β-Galactosidase-Activated Fluorogenic Reporter for the Detection of Gastric Cancer In Vivo and in Urine.
- Artificial intelligence model for perigastric blood vessel recognition during laparoscopic radical gastrectomy with D2 lymphadenectomy in locally advanced gastric cancer.
- Marine fungus-derived alkaloid inhibits the growth and metastasis of gastric cancer via targeting mTORC1 signaling pathway.
- Long noncoding RNA OVAAL enhances nucleotide synthesis through pyruvate carboxylase to promote 5-fluorouracil resistance in gastric cancer.
- Targeting autophagy peptidase ATG4B with a novel natural product inhibitor Azalomycin F4a for advanced gastric cancer.
- Immune-Related LncRNAs to Construct a Prognosis Risk-Assessment Model for Gastric Cancer.
- Nomogram for predicting mandatory ICU admission after gastrectomy for gastric cancer.
- Development and validation of a nomogram to predict intraoperative blood transfusion for gastric cancer surgery.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status13
- Large Language Models Assist in Tumor MDT
- Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
- Sintilimab Plus FOLFIRI as Second-line Therapy for Patients With HER2-negative Advanced Gastric Cancer
- Feasibility and Safety of Robotic Assisted Proximal Gastrectomy With Double-flap Technique for Proximal Early Gastric Cancer
- Laparoscopic Proximal Gastrectomy With Double-flap Technique Versus Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction for Proximal Early Gastric Cancer
- Gastric-type Endocervical Adenocarcinoma: a Population-based Cohort Study
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
- Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
- Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
- A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
Cancer
Hepatoblastoma
肝母细胞瘤Led 2 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 1.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Guangzhou for hepatoblastoma86 hospitals in China for hepatoblastoma
No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Osteosarcoma
骨肉瘤Led 6 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
30 hospitals in Guangzhou for osteosarcoma570 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led6
- HP1 enhances radio- and chemotherapy resistance in osteosarcoma via PARP1-dependent transcriptional repression and HR repair.
- SETD8 inhibits apoptosis and ferroptosis of Ewing's sarcoma through YBX1/RAC3 axis.
- AURKA inhibition induces Ewing's sarcoma apoptosis and ferroptosis through NPM1/YAP1 axis.
- DNA Damage-Sensitized metal phenolic nanosynergists potentiate Low-Power phototherapy for osteosarcoma therapy.
- ERRα contributes to HDAC6-induced chemoresistance of osteosarcoma cells.
- IGF2BP1-regulated expression of ERRα is involved in metabolic reprogramming of chemotherapy resistant osteosarcoma cells.
Earlier papers (2016–2020)5
- Epigenetic Profiling Identifies LIF as a Super-enhancer-Controlled Regulator of Stem Cell-like Properties in Osteosarcoma.
- Nanoparticle enhanced combination therapy for stem-like progenitors defined by single-cell transcriptomics in chemotherapy-resistant osteosarcoma.
- Oestrogen-related receptor alpha mediates chemotherapy resistance of osteosarcoma cells via regulation of ABCB1.
- Super-enhancer-associated MEIS1 promotes transcriptional dysregulation in Ewing sarcoma in co-operation with EWS-FLI1.
- Estrogen-related receptor α participates transforming growth factor-β (TGF-β) induced epithelial-mesenchymal transition of osteosarcoma cells.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
12 hospitals in Guangzhou for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Cancer
Neuroblastoma
神经母细胞瘤Led 10 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.9%.
- Open trials as a site
- 0
- led by another institution
22 hospitals in Guangzhou for neuroblastoma321 hospitals in China for neuroblastoma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingArsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06933394
Age 18 months to 18 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led10
- Salvage chemotherapy regimens with arsenic trioxide for relapsed or refractory neuroblastoma: a promising approach.
- Arsenic trioxide induces ferroptosis in neuroblastoma by mediating GPX4 transcriptional inhibition.
- Arsenic Trioxide inhibits Activation of Hedgehog Pathway in Human Neuroblastoma Cell Line SK-N-BE(2) Independent of Itraconazole.
- Serum brain-derived neurotrophic factor (BDNF) as predictors of childhood neuroblastoma relapse.
- Development and validation of a nomogram based on common biochemical indicators for survival prediction of children with high-risk neuroblastoma: A valuable tool for resource-limited hospitals.
- α-Synuclein Induces Neuroinflammation Injury through the IL6ST-AS/STAT3/HIF-1α Axis.
- Arsenic trioxide induces the differentiation of retinoic acid-resistant neuroblastoma cells via upregulation of HoxC9.
- Arsenic trioxide increases apoptosis of SK-N-BE (2) cells partially by inducing GPX4-mediated ferroptosis.
- Excellent Early Outcomes of Combined Chemotherapy With Arsenic Trioxide for Stage 4/M Neuroblastoma in Children: A Multicenter Nonrandomized Controlled Trial.
- Improved Outcomes with Induction Chemotherapy Combined with Arsenic Trioxide in Stage 4 Neuroblastoma: A Case Series.
Chinese-language papers (not in the count)2
Earlier papers (2016–2020)6
- Pre-application of arsenic trioxide may potentiate cytotoxic effects of vinorelbine/docetaxel on neuroblastoma SK-N-SH cells.
- α-synuclein accumulation in SH-SY5Y cell impairs autophagy in microglia by exosomes overloading miR-19a-3p.
- Arsenic trioxide induces cell cycle arrest and affects Trk receptor expression in human neuroblastoma SK-N-SH cells.
- Analysis of treatment of large abdominal malignancies in children complicated with abdominal compartment syndrome: Report of six cases.
- Rifampicin inhibits rotenone-induced microglial inflammation via enhancement of autophagy.
- Low dose of arsenic trioxide inhibits multidrug resistant-related P-glycoprotein expression in human neuroblastoma cell line.
Cancer
Ewing sarcoma
尤文肉瘤Led 2 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Guangzhou for Ewing sarcoma134 hospitals in China for Ewing sarcoma
No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 1 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.06%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
14 hospitals in Guangzhou for multiple myeloma175 hospitals in China for multiple myeloma
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1
- Started
- 2024-06
- Registry
- NCT06574568
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Jinan, Taiyuan, Zhengzhou
- Not yet recruitingClinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07569757
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status4
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病Led 4 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 1.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
8 hospitals in Guangzhou for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingStudy of YK012 in B-cell Acute Lymphoblastic Leukemia
- Phase
- Phase 1/Phase 2
- Started
- 2024-09
- Registry
- NCT06580301
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangchun, Guangzhou, Guiyang, Hangzhou, Nanchang, Xuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led4
- The potential role of RNA sequencing in diagnosing unexplained insensitivity to conventional chemotherapy in pediatric patients with B-cell acute lymphoblastic leukemia.
- TARGET based m6A methylation-related genes predict prognosis relapsed B-cell acute lymphoblastic leukemia.
- Prognosis of pediatric BCP-ALL with IKZF1 deletions and impact of intensive chemotherapy: Results of SCCLG-2016 study.
- The RAS-signaling-pathway-mutation-related prognosis in B-cell acute lymphoblastic leukemia: A report from South China children's leukemia group.
Chinese-language papers (not in the count)1
Blood disorders
Haemophagocytic lymphohistiocytosis
噬血细胞性淋巴组织细胞增生症Led 4 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 1.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
5 hospitals in Guangzhou for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
- Phase
- Phase 3
- Started
- 2025-11
- Registry
- NCT07208058
Age 16 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led4
- Prognostic scoring model incorporating clinical characteristics for pediatric hemophagocytic lymphohistiocytosis: a multicenter retrospective study.
- Retrospective analysis of ruxolitinib as induction treatment in pediatric hemophagocytic lymphohistiocytosis.
- Treatment of pediatric refractory or relapsed Epstein-Barr virus-associated hemophagocytic syndrome with PD-1 inhibitors.
- Analysis of clinical characteristics and prognostic factors associated with EBV-associated HLH in children.
All its trials on ClinicalTrials.gov, any status1
More papers found outside PubMed (not counted)1
Blood disorders
Beta thalassaemia
β 地中海贫血Led 6 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 1.9%.
- Open trials led
- 0
- recruiting or about to
18 hospitals in Guangzhou for beta thalassaemia133 hospitals in China for beta thalassaemia
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
- Phase
- Phase 1
- Started
- 2024-01
- Registry
- NCT06465550
Age 3 years to 35 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Nanning, Shanghai
- RecruitingStudy of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
- Phase
- Phase 2
- Started
- 2019-11
- Registry
- NCT04143724
Age 6 years to 17 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChengdu, Guangzhou, Nanning, Shenzhen
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led6
- Clinical patterns of thalidomide in the treatment of transfusion-dependent β-thalassaemia in children: a prospective single-arm study in China.
- A Chinese pediatric patient with thalassemia traits and compound heterozygous mutations in the PIEZO1 gene suspected of having dehydrated hereditary stomatocytosis.
- Identification of a Patient with Transfusion-Dependent β-Thalassemia Caused by Compound Heterozygous Mutations of HBB: C.84_85insC and Common Linked Intronic Variants in HBB.
- Creating New Cis-Regulatory Elements of HBD to Reactivate Delta-Globin.
- A novel conditioning regimen with pre-transplantation immunosuppression reduces the complication rates in hematopoietic stem cell transplantation in transfusion-dependent β-thalassemia.
- Indicators of glucose dysregulation and the relationship with iron overload in Chinese children with beta thalassemia major.
Chinese-language papers (not in the count)2
Earlier papers (2016–2020)7
- Severe hypertension is an independent risk factor for posterior reversible encephalopathy syndrome post-hematopoietic cell transplantation in children with thalassemia major.
- Modified conditioning regimen improves outcomes of unrelated donor peripheral blood stem cell transplantation for β-thalassaemia major patients.
- Hematopoietic stem cell transplantation for children with β-thalassemia major: multicenter experience in China.
- [Clinical analysis of three cases with beta-thalassemia].
- Mitophagy is increased during erythroid differentiation in β-thalassemia.
- [A clinical analysis of micafungin treatment of pulmonary invasive fungal infection in pediatric patients with acute leukemia or post hematopoietic stem cells transplantation].
- [Analysis of the influence of iron overload in glucose metabolism in thalassemia major patients].
All its trials on ClinicalTrials.gov, any status5
- Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing Factors
- The Safety and Efficiency of Luspatercept in Chinese Adults With Transfusion Dependent β-thalassemia: a Real-world Study
- A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
- Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
- Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia
Other diseases
Neuromyelitis optica spectrum disorder
视神经脊髓炎谱系疾病9 hospitals in Guangzhou for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingSun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases
- Phase
- Not given
- Started
- 2024-01
- Registry
- NCT06541626
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingA Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- Phase
- Phase 2/Phase 3
- Started
- 2024-07
- Registry
- NCT06413654
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status3
More papers found outside PubMed (not counted)1
Other diseases
IgG4-related disease
IgG4相关性疾病Led 4 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 1.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Guangzhou for IgG4-related disease46 hospitals in China for IgG4-related disease
No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led4
- IgG4-related disease with nasopharyngeal malignancy-like manifestations.
- The risk of malignancy in patients with IgG4-related disease: a systematic review and meta-analysis.
- The function of IL-33/ST2 signaling axis in treg cells activating fibrosis in IgG4-related disease.
- Clinicopathological characteristics of IgG4-related lung disease.
Chinese-language papers (not in the count)1
More papers found outside PubMed (not counted)4
- Additional file 3 of TSLP promoting B cell proliferation and polarizing follicular helper T cell as a therapeutic target in IgG4-related disease
- AB0125 CLINICAL CHARACTERISTICS OF RHEUMATOID ARTHRITIS PATIENTS WITH IGG4-RELATED SYNOVITIS
- An overlap of antineutrophil cytoplasmic antibody-associated vasculitis and IgG4-related disease: distinct clinicopathologic clues for precise diagnosis
- MO144OVERLAP SYNDROME OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS AND IGG4-RELATED DISEASE: DISTINCT CLINICOPATHOLOGIC CLUES FOR PRECISE DIAGNOSIS
Other diseases
Hepatic echinococcosis
肝包虫病Led 1 of the 152 English-language PubMed papers on hepatic echinococcosis with an author in mainland China, 2021–2025: 0.7%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Guangzhou for hepatic echinococcosis44 hospitals in China for hepatic echinococcosis
No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 3 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
13 hospitals in Guangzhou for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Inferring the genetic relationship between brain imaging-derived phenotypes and risk of complex diseases by Mendelian randomization and genome-wide colocalization.
- NRF2 activation suppresses motor neuron ferroptosis induced by the SOD1G93A mutation and exerts neuroprotection in amyotrophic lateral sclerosis.
- MPO/HOCl Facilitates Apoptosis and Ferroptosis in the SOD1G93A Motor Neuron of Amyotrophic Lateral Sclerosis.
Other diseases
Behçet disease
白塞病Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
7 hospitals in Guangzhou for Behçet disease139 hospitals in China for Behçet disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
- Phase
- Phase 3
- Started
- 2023-11
- Registry
- NCT06145893
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
Other diseases
IgA nephropathy
IgA 肾病Led 7 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
16 hospitals in Guangzhou for IgA nephropathy300 hospitals in China for IgA nephropathy
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingCorrelation of Microbiome and Metabonomics With IgA Nephropathy
- Phase
- Not given
- Started
- 2020-05
- Registry
- NCT05190848
Age 16 years to 65 years (registered criteria)
Led by Guangdong Provincial People's Hospital; 4 listed hospitals as study sitesGuangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led7
- Dynamics of chromatin accessibility governing Gd-IgA1 synthesis in B cells associated with IgA nephropathy.
- Development and validation of a diagnostic nomogram to evaluate tubular atrophy/interstitial fibrosis of IgA nephropathy.
- Association between geriatric nutritional risk index and pathological phenotypes of IgA nephropathy.
- Serum homocysteine is associated with tubular interstitial lesions at the early stage of IgA nephropathy.
- Plasma exosomal IRAK1 can be a potential biomarker for predicting the treatment response to renin-angiotensin system inhibitors in patients with IgA nephropathy.
- Identifying DUSP-1 and FOSB as hub genes in immunoglobulin A nephropathy by WGCNA and DEG screening and validation.
- New COL4A5 mutation in IgA nephropathy.
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status1
Other diseases
Osteogenesis imperfecta
成骨不全症Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Guangzhou for osteogenesis imperfecta58 hospitals in China for osteogenesis imperfecta
No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
9 hospitals in Guangzhou for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingFIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07296458
Age 18 years to 75 years (registered criteria)
Led by Xijing Hospital; 1 listed hospital as study siteGuangzhou, Xi'an
- RecruitingFenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
- Phase
- Phase 2/Phase 3
- Started
- 2023-02
- Registry
- NCT05749822
Age 18 years to 75 years (registered criteria)
Led by Xijing Hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Kunming, Nanjing, Shenyang, Tianjin, Xi'an, Yan'an, Zhengzhou
- RecruitingFenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
- Phase
- Phase 3
- Started
- 2023-02
- Registry
- NCT05751967
Age 18 years to 75 years (registered criteria)
Led by Xijing Hospital; 6 listed hospitals as study sitesChengdu, Guangzhou, Lanzhou, Nanjing, Shenyang, Tianjin, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status5
- FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy
- Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
- Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
- A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics
- Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis
Other diseases
Primary sclerosing cholangitis
原发性硬化性胆管炎Led no English-language PubMed papers on primary sclerosing cholangitis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Guangzhou for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis
No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other linked evidence
Getting in touch
Name card to show staff or a driver
中山大学孙逸仙纪念医院
Sun Yat-sen Memorial Hospital
广州
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Sun Yat-Sen Memorial Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; First Affiliated Hospital and Sun Yat-sen Memorial Hospital; Sun Yat-sen Memorial Hospital Affiliated to Sun Yat-sen University; Sun Yat-sen Memorial Hospitall; Sun Yatsen Memorial Hospital of Sun Yat-sen University; Second Affiliated Hospital of Sun Yat-sen